Salts of the janus kinase inhibitor (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
View Patent ↗The present invention provides salt forms of (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that are useful in the modulation of Janus kinase activity and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
1. A method of treating a cancer selected from the group consisting of breast cancer, Castleman's disease, pancreatic cancer, and leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt, wherein said treating refers to ameliorating or inhibiting the disease in a patient.
2. The method of claim 1 , wherein the cancer is pancreatic cancer.
3. The method of claim 1 , wherein the cancer is breast cancer.
4. The method of claim 1 , wherein the cancer is leukemia.
5. The method of claim 4 , wherein the cancer is chronic myelogenous leukemia (CML).
6. The method of claim 4 , wherein the cancer is acute myelogenous leukemia (AML).
7. The method of claim 4 , wherein the cancer is acute lymphoblastic leukemia (ALL).
8. The method of claim 4 , wherein the cancer is chronic myelomonocytic leukemia (CMML).
9. The method of claim 1 , wherein (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt is a crystalline salt.
10. The method of claim 9 , wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.
11. A method of treating a cancer selected from the group consisting of breast cancer, Castleman's disease, pancreatic cancer, and leukemia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition comprising (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt and a pharmaceutically acceptable carrier, wherein said treating refers to ameliorating or inhibiting the disease in a patient.
12. The method of claim 11 , wherein the cancer is pancreatic cancer.
13. The method of claim 11 , wherein the cancer is breast cancer.
14. The method of claim 11 , wherein the cancer is leukemia.
15. The method of claim 14 , wherein the cancer is chronic myelogenous leukemia (CML).
16. The method of claim 14 , wherein the cancer is acute myelogenous leukemia (AML).
17. The method of claim 14 , wherein the cancer is acute lymphoblastic leukemia (ALL).
18. The method of claim 14 , wherein the cancer is chronic myelomonocytic leukemia (CMML).
19. The method of claim 11 , wherein the pharmaceutical composition is suitable for oral administration.
20. The method of claim 11 , wherein the pharmaceutical composition is in tablet form.
21. The method of claim 11 , wherein (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt is a crystalline salt.
22. The method of claim 21 , wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.
23. A method of treating cachexia in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound that is (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt, wherein said treating refers to ameliorating or inhibiting the disease in a patient.
24. The method of claim 23 , wherein the cachexia results from or is associated with cancer.
25. The method of claim 23 , wherein (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphoric acid salt is a crystalline salt.
26. The method of claim 23 , wherein said crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt.